期刊文献+

靶向RANKL基因的siRNA对成骨细胞促破骨细胞生成作用的影响 被引量:3

The Effect of siRNA Targeting RANKL on Osteoclastogenesis Induced by Osteoblast in Vitro
下载PDF
导出
摘要 目的利用RNA干扰(RNAi)技术抑制大鼠成骨细胞核激活因子受体配体(Ligand of receptor activator of NF-κB,RANKL)的表达,观察成骨细胞RANKL/OPG比值的变化,探讨成骨细胞与破骨细胞生成的相关性。方法合成4条RANKL序列特异性小干扰RNA(siRNA),用Liopfectamin2000转染成骨细胞,采用荧光实时定量聚合酶链反应(PCR)检测RANKL的表达,筛选出最有效的干扰序列,并用Western blot技术检测成骨细胞的RANKL、OPG的表达,观察RANKL/OPG比例的变化,采用成骨细胞破骨细胞共培养技术探讨转染后的成骨细胞对破骨细胞生成的影响。结果合成的4对siRNA中有一对可使大鼠成骨细胞的RANKL mRNA水平下降89%,蛋白表达下降76%;同时OPG的蛋白表达无明显变化,RANKL/OPG比例明显下调,破骨细胞的生成明显受到抑制。结论RNAi沉默RANKL基因表达可显著下调成骨细胞RANKL/OPG的比值,抑制破骨细胞的生成。 Objective To observe the change of the ratio of ligand of receptor activator of NF-κB(RANKL) and Osteoprotegerin (OPG) in responds to silencing of the expression RANKL with RNA interference( RNAi ), and explore the relationship between osteoblast and osteoclastogenesis. Methods Four synthesized small interference RNA (siRNA ) were transfected into osteoblast using Lipofectamin2000.RANKL mRNA level was determined by real-time quantitative reverse transcriptase polymerase chain reaction( RT-PCR). Western blot was employed to analyze the expression of RANKL and OPG,then the change of ratio of RANKL and OPG was observed. The tmnsfected cells and primary rat bone marrow cells were cocultured to explore the osteoclastogenesis induced by osteoblast. Results The most effective sequence was found out among the 4 candidates. Single dose of this siRNA caused nearly 89% loss of RNAKL mRNA and 76% loss of RANKL protein in osteoblast, although no significant change was found for OPG.The ratio of RANKL/OPG and the potential of the osteoblasts were significantly reduced. Conclusion These results provided RANKL was vulnerable to RNA interference and RANKL silencing by RNAi could significantly reduce the the ratio of RANKL/OPG and inhibit the formation of osteoclast.
出处 《四川医学》 CAS 2007年第6期575-577,共3页 Sichuan Medical Journal
基金 国家自然科学基金资助项目(项目编号:30571871)
关键词 核激活因子受体配体 RNA干扰 大鼠 成骨细胞 基因沉默 ligang of receptor activator of NF-κB RNA interference rat osteoblast gene silence
  • 相关文献

参考文献8

  • 1Tanaka S,NakamuraK,Takahasi N,et al.Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKLRANK signaling system[J].Imnamol Rev,2005,208:30~49
  • 2Fire A,Xu S,Montgomery MK,et al.Potent and specific genetic interference bydouble-stranded RNA in Caenorhabditis elegans[J].Nature,1998,391(6669):806~811
  • 3Udagawa N,Horwood NJ,Elliott J,et al.Interleukin-18(intefferong-indueing factor)is produced by osteoblastsand acts via granulocyte/maerophage colony-stimulating factor and not via interferong to inhibit osteoclast formation[J].J Exp Med,1997,185(6):1005~1012
  • 4Tabara H,Grishok A,Mello CC.et al.RNAi in C.elegans:soaking in the genome sequence[J].Science,1998,282(5388):430~431
  • 5Park EK,Kim MS,Lee SH,et al.Furosin,all ellagitannin,suppresses RANKL-induced osteoclast differentiation and function througy inhibition of MAP kinase activation and actin ring formation[J].Biochem Biophys Res Conmaun,2004,325(4):1472~1480
  • 6Body JJ,Greipp P,Coleman RE,et al.A phase I study of AMGN-007,a recombinant osteoprotegerin construct,in patients with multiple myeloma or breast carcinoma related bone metastases[J].Cancer,2003,97(3 Suppl):887~892
  • 7Bekker PJ,Holloway DL,Rasmussen AS,et al.A single-dose placebo-controlled study of AMG 162,a fully human monoclonal antibody to RANKL,in postmenopausal women[J].J Bone Miner Res,2004,19(7):1059~1066
  • 8Weiner LM.Fully human therapeutic monodonal antibodies[J].J Immunother,2006,29(1):1~9

同被引文献31

  • 1Greenfield EM, Bechtold J, Implant Wear Sympium 2007 Biologic Work Group. What other biologic and mechanical factors night contribute to osteolysis? J Am Acad Orthop Surg, 2008; 16(Suppl 1):S56-S62.
  • 2Hoeuauer LC, Heufelder AE. Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases. Dtsch Med Wochenschr, 2001 ; 126(6) : 145-150.
  • 3Dehm SM, Bonham K SRC gene expression in human cancer: the role of transcriptional activations. Biochem Cell Biol. 2004; 82(2):263-274.
  • 4Yang S, Glen W, Stashenko P, et al. Specificity of RGS10A as a key component in the RANKI. signaling mechanism for osteoclast differentiation. J Cell Sci, 2007; 120(Pt 19) :3362-3371.
  • 5Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutalions in the gene encoding RANKL Nat Genet, 2007; 39(8) : 960-962.
  • 6Nakamichi Y, Udagawa N, Kobayashi Y, et al. Osteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblasts. J Immunol, 2007; 178(1):102-200.
  • 7Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med, 2002,347(3):175-184.
  • 8Ren W, Wu B, Peng X, et al. Erythmmycin inhibits wear debris-induced inflammatory osteolysis in a murine model. J Orthop Res, 2006; 24(2):280-290.
  • 9Rarnage SC, Urban NH, Jiranek WA. Expression of RANKL in osteolytic membranes association with fibroblastic cell markers. J Bone Joint Surg Am, 2007; 89(4) :841-848.
  • 10Veigl D, Niedeflova J, Krysulfkova O. Periprosthetic osteolysis and its association with RANKL expression. Physiol Res, 2007, 56(4):455-462.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部